Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 6:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 167 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Adult Immune Response Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults

NCT00118924
View directory record Official record
Conditions
Tick-Borne Encephalitis
Interventions
LGT(TP21)/DEN4, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2008 · Synced Sep 22, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults

NCT00428337
View directory record Official record
Conditions
HIV Infections
Interventions
EP-1233, MVA-mBN32
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
3
States / cities
San Francisco, California • Rochester, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 22, 2026, 6:50 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

NCT05047770
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su, Flu D-QIV, mRNA-1273
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,013 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
46
States / cities
Tempe, Arizona • Oxnard, California • San Diego, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 22, 2026, 6:50 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

NCT04886154
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo, MenB vaccine, MenACWY vaccine
Combination Product · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 50 Years
Enrollment
1,440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
12
States / cities
Colorado Springs, Colorado • Longmont, Colorado • Doral, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Sep 22, 2026, 6:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults

NCT06431607
View directory record Official record
Conditions
Influenza, Human
Interventions
F2G22B/DL001Z, F2H23D/DL001Z-NH, F2H23B/DL001Z-NH, F2H23H/DL001Z, FDQ23A-NH (Flu D-QIV), GSK5800544A, Flu D-TIV, F2H23A/DL001Z-NH, F2H23G/DL001Z, Fluzone HD Quadrivalent, Fluzone HD
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 85 Years
Enrollment
845 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
18
States / cities
Hialeah, Florida • Miami, Florida • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 22, 2026, 6:50 PM EDT
Completed Phase 1 Interventional

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults

NCT05968989
View directory record Official record
Conditions
Influenza
Interventions
VRC-FLUMOS0116-00-VP( FLUMos-v2)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 22, 2026, 6:50 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Studying Cell Immune Responses to a Live Flu Vaccine in Healthy Adults

NCT01730144
View directory record Official record
Conditions
Normal Physiology
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Sep 22, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults

NCT00094705
View directory record Official record
Conditions
Dengue Fever
Interventions
rDEN2/4delta30(ME) Vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 20, 2008 · Synced Sep 22, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Candidate HIV Vaccine

NCT00089531
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA016-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 44 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 22, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults

NCT02392325
View directory record Official record
Conditions
Dengue
Interventions
rDEN1Δ30, Placebo, rDEN2Δ30-7169
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Sep 22, 2026, 6:50 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria

NCT00870987
View directory record Official record
Conditions
Malaria
Interventions
DNA vaccine prime, adenovirus type 5 vaccine boost
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 22, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults

NCT01578889
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-MAG vaccine, IL-12 pDNA adjuvant, VSV HIV gag vaccine, Placebo, Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device
Biological · Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
5
States / cities
New York, New York • Rochester, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Sep 22, 2026, 6:50 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults

NCT06620003
View directory record Official record
Conditions
Marburg Virus Disease
Interventions
cAd3-Marburg Vaccine, Placebo
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
7
States / cities
Huntsville, Alabama • Phoenix, Arizona • Melbourne, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 22, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Immune Response to Heplisav in Healthy Older Adults

NCT01999699
View directory record Official record
Conditions
Hepatitis B
Interventions
HEPLISAV
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
50 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Sep 22, 2026, 6:50 PM EDT
Completed Phase 1 Interventional

Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection

NCT01915212
View directory record Official record
Conditions
Healthy Volunteers
Interventions
HSV529, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 22, 2026, 6:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.

NCT02564471
View directory record Official record
Conditions
Rabies
Interventions
Chloroquine, Atovaquone and Proguanil, Doxycycline, Rabies Vaccine
Drug · Biological
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 60 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 22, 2026, 6:50 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers

NCT00952185
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm, Viral Infection
Interventions
cytology specimen collection procedure, fluorescent antibody technique, assessment of therapy complications
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 22, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and Adults

NCT00366782
View directory record Official record
Conditions
Paramyxoviridae Infections, Virus Diseases
Interventions
rB/HPIV3, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 49 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 29, 2012 · Synced Sep 22, 2026, 6:50 PM EDT
Completed Phase 1 Interventional

Ebola and Marburg Virus Vaccines

NCT00605514
View directory record Official record
Conditions
Ebola Vaccines, Marburg Virus Disease, Ebola Virus Disease, Marburgvirus, Ebolavirus
Interventions
VRC-EBODNA023-00-VP, VRC-MARDNA025-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 22, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults

NCT00375726
View directory record Official record
Conditions
Dengue
Interventions
rDEN3/4delta30(ME), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 13, 2010 · Synced Sep 22, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults

NCT01479296
View directory record Official record
Conditions
HIV Infections
Interventions
VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C), rAd5 env A, rAd5 env B, rAd5 env C, rAd5 gag-pol, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Sep 22, 2026, 6:50 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection

NCT06908096
View directory record Official record
Conditions
EBV, Epstein-Barr Virus Infection, Infectious Mononucleosis, Mono
Interventions
EBV gp350-ferritin vaccine with ALFQ adjuvant, EBV gH/gL/gp42-ferritin nanoparticle vaccine with ALFQ adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 29 Years
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 22, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults

NCT02296541
View directory record Official record
Conditions
HIV Infections
Interventions
DNA Nat-B env, DNA CON-S env, DNA Mosaic env, MVA-CMDR, Placebo for DNA Nat-B env, Placebo for DNA CON-S env, Placebo for DNA Mosaic env, Placebo for MVA-CMDR
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced Sep 22, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults

NCT00831012
View directory record Official record
Conditions
Dengue Fever
Interventions
rDEN3delta30/31-7164
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Sep 22, 2026, 6:50 PM EDT